The long-term efficacy and safety of fecal microbiota transplant for recurrent, severe, and complicated clostridium difficile infection in 146 elderly individuals

Journal of Clinical Gastroenterology

Volumn 50, Issue 5, 2016, Pages 403-407

  Agrawal, Manasi ^a   Aroniadis, Olga C ^a   Brandt, Lawrence J ^a   Kelly, Colleen ^b   Freeman, Sarah ^b   Surawicz, Christina ^c   Broussard, Elizabeth ^c   Stollman, Neil ^d   Giovanelli, Andrea ^d   Smith, Becky ^e   Yen, Eugene ^e   Trivedi, Apurva ^f   Hubble, Levi ^f   Kao, Dina ^g   Borody, Thomas ^h   Finlayson, Sarah ^h   Ray, Arnab ⁱ   Smith, Robert ⁱ  

^a MONTEFIORE MEDICAL CENTER   (United States)

^b BROWN UNIVERSITY   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d Northern California Gastroenterology Associates   (United States)

^e NORTHSHORE UNIVERSITY HEALTHSYSTEM   (United States)

^f SCOTT AND WHITE MEMORIAL HOSPITAL   (United States)

^g UNIVERSITY OF ALBERTA   (Canada)

^h Centre for Digestive Diseases   (Australia)

ⁱ OCHSNER MEDICAL CENTER   (United States)

Author keywords

Clostridium difficile infection; Elderly; Fecal microbiota transplant

Indexed keywords

FIDAXOMICIN; METRONIDAZOLE; VANCOMYCIN;

AGED; ARTICLE; CLOSTRIDIUM DIFFICILE INFECTION; COLON PERFORATION; CONSTIPATION; CONTACT DERMATITIS; DIARRHEA; DRUG TREATMENT FAILURE; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; HOSPITAL ADMISSION; HUMAN; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; MICROSCOPIC COLITIS; MULTICENTER STUDY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RECURRENCE RISK; SJOEGREN SYNDROME; VERY ELDERLY; ADVERSE EFFECTS; AGE; CLINICAL TRIAL; CLOSTRIDIUM INFECTIONS; ISOLATION AND PURIFICATION; MICROBIOLOGY; PEPTOCLOSTRIDIUM DIFFICILE; PROCEDURES; QUESTIONNAIRE; RECURRENT DISEASE; RETROSPECTIVE STUDY; SEVERITY OF ILLNESS INDEX; TIME FACTOR; TREATMENT OUTCOME;

AGE FACTORS; AGED; AGED, 80 AND OVER; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; FECAL MICROBIOTA TRANSPLANTATION; FEMALE; HUMANS; MALE; RECURRENCE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVEYS AND QUESTIONNAIRES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84944345399     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0000000000000410     Document Type: Article

References (31)

1. Lucado J, Gould C, Elixhauser A. Clostridium difficile Infections (CDI) in Hospital Stays, 2009: Statistical Brief #124 Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. Rockville, MD: Agency for Health Care Policy and Research (US); 2006-2012.
2. Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999-2004. Emerg Infect Dis. 2007;13:1417-1419.
3. Hu MY, Katchar K, Kyne L, et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology. 2009;136:1206-1214.
4. Riggs MM, Sethi AK, Zabarsky TF, et al. Asymptomatic carriers are a potential source for transmission of epidemic and nonepidemic Clostridium difficile strains among long-term care facility residents. Clin Infect Dis. 2007;45:992-998.
5. Kyne L, Sougioultzis S, McFarland LV, et al. Underlying disease severity as a major risk factor for nosocomial Clostridium difficile diarrhea. Infect Control Hosp Epidemiol. 2002;23:653-659.
6. Archibald LK, Banerjee SN, Jarvis WR. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001. J Infect Dis. 2004;189:1585-1589.
7. Stevens V, Dumyati G, Fine LS, et al. Cumulative antibiotic exposures over time and the risk of Clostridium difficile infection. Clin Infect Dis. 2011;53:42-48.
8. Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med. 2000;342:390-397.
9. Loo VG, Bourgault AM, Poirier L, et al. Host and pathogen factors for Clostridium difficile infection and colonization. N Engl J Med. 2011;365:1693-1703.
10. Fenner L, Frei R, Gregory M, et al. Epidemiology of Clostridium difficile-associated disease at University Hospital Basel including molecular characterisation of the isolates 2006- 2007. Eur J Clin Microbiol Infect Dis. 2008;27:1201-1207.
11. Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet. 2001;357:189-193.
12. Surawicz CM, Brandt LJ, Binion DG, et al. Guidelines for diagnosis, treatment, and prevention of Clostridium difficile infections. Am J Gastroenterol. 2013;108:478-498.
13. Cober ED, Malani PN. Clostridium difficile infection in the "oldest" old: clinical outcomes in patients aged 80 and older. J Am Geriatr Soc. 2009;57:659-662.
14. Louie TJ, Miller MA, Crook DW, et al. Effect of age on treatment outcomes in Clostridium difficile infection. J Am Geriatr Soc. 2013;61:222-230.
15. Kelly CR, Kahn S, Kashyap P, et al. Update on fecal microbiota transplantation 2015: indications, methodologies, mechanisms, and outlook. Gastroenterology. 2015;149:223-237.
16. van Nood E, Vrieze A, Nieuwdorp M, et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl JMed. 2013;368:407-415.
17. Brandt LJ, Aroniadis OC, Mellow M, et al. Long-term follow-up of colonoscopic fecal microbiota transplant for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107:1079-1087.
18. HamiltonMJ, Weingarden AR, Sadowsky MJ, et al. Standardized frozen preparation for transplantation of fecal microbiota for recurrent Clostridium difficile infection. Am J Gastroenterol. 2012;107:761-767.
19. Mattila E, Uusitalo-Seppälä R, Wuorela M, et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology. 2012;142:490-496.
20. Lee CH, Belanger JE, Kassam Z, et al. The outcome and longterm follow-up of 94 patients with recurrent and refractory Clostridium difficile infection using single to multiple fecal microbiota transplantation via retention enema. Eur J Clin Microbiol Infect Dis. 2014;33:1425-1428.
21. Grehan MJ, Borody TJ, Leis SM, et al. Durable alteration of the colonic microbiota by the administration of donor fecal flora. J Clin Gastroenterol. 2010;44:551-561.
22. Khoruts A, Dicksved J, Jansson JK, et al. Changes in the composition of the human fecal microbiome after bacteriotherapy for recurrent Clostridium difficile-associated diarrhea. J Clin Gastroenterol. 2010;44:354-360.
23. Brandt LJ, Aroniadis OC. An overview of fecal microbiota transplantation: techniques, indications, and outcomes. Gastrointest Endosc. 2013;78:240-249.
24. Kelly CR, de Leon L, Jasutkar N. Fecal microbiota transplantation for relapsing Clostridium difficile infection in 26 patients: methodology and results. J Clin Gastroenterol. 2012;46:145-149.
25. Burke KE, Lamont JT. Fecal transplantation for recurrent Clostridium difficile infection in older adults: a review. J Am Geriatr Soc. 2013;61:1394-1398.
26. Rubin TA, Gessert CE, Aas J. Stool transplantation for older patients with Clostridium difficile infection. J Am Geriatr Soc. 2009;57:2386-2387.
27. Jalanka-Tuovinen J, Salojärvi J, Salonen A. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut. 2014;63:1737-1745.
28. Grinspan A, Bernheim OE, Yousefzadeh E, et al. Clostridium difficile as a causative agent of post-infection irritable bowel syndrome (PI-IBS). Gastroenterology. 2008;134:A91. (#637).
29. Kelly CR, Ihunnah C, FischerM, et al. Fecal microbiota transplant for treatment of Clostridium difficile infection in immunocompromised patients. Am J Gastroenterol. 2014;109:1065-1071.
30. Zainah H, Silverman A. Fecal bacteriotherapy: a case report in an immunosuppressed patient with ulcerative colitis and recurrent Clostridium difficile infection. Case Rep Infect Dis. 2012;2012:810943.
31. Borody TJ, Brandt LJ, Paramsothy S, et al. Fecal microbiota transplantation: a new standard treatment option for Clostridium difficile. Expert Rev Anti Infect Ther. 2013;11:447-449.